Petrelintide for Weight Loss: What the 2026 Lancet Trial Shows and How It Compares to GLP-1s
Petrelintide (RO7771831), Roche’s investigational once-weekly amylin analog, produced roughly 10.7% weight loss at 42 weeks in a Phase 2 randomized trial published in The Lancet Diabetes & Endocrinology in September 2026 — and it did so with nausea rates much closer to placebo than typical GLP-1 drugs deliver. The drug is not FDA-approved and is not yet commercially available; however, it represents the most clinically credible alternative mechanism for obesity treatment to emerge in years. If you’re currently struggling with GLP-1 side effects or have not yet started a medically supervised weight loss program, a licensed telehealth provider can help you navigate what is available today.
What is petrelintide and why does the medical community care?
Amylin is a hormone secreted alongside insulin by pancreatic beta cells. It slows gastric emptying, suppresses glucagon, and reduces appetite — roughly speaking, it tells your brain “I’ve eaten enough” through a different pathway than GLP-1s do. The FDA approved a synthetic amylin analog called pramlintide (Symlin) in 2005 for people with type 1 and type 2 diabetes, but it required multiple daily injections and was rarely used.
Petrelintide is a next-generation, long-acting amylin analog engineered for once-weekly dosing — the same convenience as Ozempic or Zepbound. The hypothesis driving Roche’s investment: because amylin and GLP-1 use different appetite-control circuits, petrelintide might produce meaningful weight loss with fewer of the nausea and vomiting episodes that lead some patients to stop GLP-1 therapy.
The Phase 2 ZUPREME-1 trial, funded by Roche, tested that hypothesis in 485 adults with obesity or overweight who did not have type 2 diabetes. Participants were randomized to petrelintide (doses from 0.5 mg to 7.0 mg weekly) or placebo for 42 weeks. The full results were published in The Lancet Diabetes & Endocrinology and drew broad coverage given how competitive the obesity drug pipeline has become.
What did the ZUPREME-1 trial actually find?
Weight loss: The highest-dose group (7.0 mg) lost 10.5% of body weight on average; across all active doses on the efficacy estimand, the mean was 10.7% versus 1.7% on placebo — a difference of approximately 9 percentage points. When all participants who enrolled were included regardless of whether they completed the trial, the figure was 10.2% vs. 1.4%.
Tolerability: Here is where petrelintide stands out relative to GLP-1s. Nausea occurred in 20% of participants on petrelintide versus 6% on placebo. Vomiting occurred in 3% on drug versus 6% on placebo — not statistically different from placebo. Diarrhea was 7% in both groups. Critically, only 1.5% of participants discontinued the trial due to GI side effects. For context, in the SURMOUNT-1 tirzepatide trial, nausea was reported in 30–32% of participants, and in the STEP-1 semaglutide trial, nausea affected up to 44% of the drug group.
What the trial did not measure: ZUPREME-1 was not powered to assess cardiovascular outcomes, and it did not include a head-to-head comparison with semaglutide or tirzepatide. The lower weight loss figure relative to approved GLP-1s (10% vs. 15–22%) is a direct limitation. A second Phase 2 trial, ZUPREME-2, in patients with type 2 diabetes and obesity, has also reported topline results, and Roche is now advancing petrelintide into Phase 3.
How does petrelintide compare to current FDA-approved weight loss options?
| Drug | Mechanism | Approx. weight loss | Nausea rate | FDA status |
|---|---|---|---|---|
| Semaglutide (Wegovy 2.4 mg) | GLP-1 receptor agonist | ~15% at 68 weeks | ~44% | Approved |
| Tirzepatide (Zepbound 15 mg) | GLP-1 + GIP receptor agonist | ~22% at 72 weeks | ~30% | Approved |
| Orforglipron (Foundayo oral) | Oral GLP-1 receptor agonist | ~9–14% at 36 weeks | ~21–32% | Approved Apr 2026 |
| Petrelintide (investigational) | Amylin analog | ~10.7% at 42 weeks | ~20% | Phase 3 (not approved) |
Sources: NEJM STEP-1, NEJM SURMOUNT-1, FDA prescribing information for Foundayo, Lancet Diabetes & Endocrinology ZUPREME-1 full publication (September 2026).
The numbers tell a nuanced story. Petrelintide’s weight loss is lower than tirzepatide’s and modestly lower than semaglutide’s, but its GI tolerability — especially the 3% vomiting rate, essentially equivalent to placebo — is genuinely differentiated. For a patient who tried Wegovy and stopped because of daily nausea, that difference is not academic.
Roche is also exploring combinations: adding petrelintide on top of a GLP-1 agonist to see whether dual-pathway stimulation can push weight loss closer to the 20%+ range with manageable side effects. Early data from that combination are expected in 2027.
Is there a weight loss drug that doesn’t cause nausea or vomiting?
This is among the most frequently asked questions on weight loss forums and AI assistants in 2026, and the honest answer is: not yet, not commercially.
Every currently approved obesity medication has some GI side effect profile. However, several strategies already in clinical use can significantly reduce nausea on GLP-1 therapy:
- Slow dose titration: The FDA-approved escalation schedule for semaglutide and tirzepatide spaces dose increases 4 weeks apart. Patients who titrate more slowly — staying at sub-maximum doses longer — often report substantially less nausea.
- Injection timing: Some patients find that injecting at bedtime, when they are asleep through the peak GI effect, reduces daytime nausea.
- Dietary adjustments: Smaller, low-fat meals and avoiding alcohol in the first weeks of treatment are clinically supported approaches. A telehealth provider can send a structured meal protocol alongside your prescription.
- Anti-nausea medications: Ondansetron or metoclopramide can be prescribed short-term during titration for patients with significant nausea.
None of these eliminate GI effects entirely, but for many patients they make the difference between staying on therapy and stopping.
When will petrelintide be available?
Based on the ZUPREME-1 publication and Roche’s public statements, petrelintide is currently entering Phase 3 trials. If Phase 3 succeeds and the FDA grants a standard 12-month PDUFA review, the earliest realistic timeline for commercial availability in the United States is 2028 to 2029. That is not a near-term option for anyone starting or restarting a weight management program today.
Roche has also indicated interest in a fixed-dose combination of petrelintide with a GLP-1 agonist, though that combination is in earlier-stage testing. The amylin + GLP-1 dual-agonist category could ultimately deliver higher efficacy with better tolerability than either drug alone, but those data are at least several years away.
What to do if GLP-1 side effects are preventing you from staying on treatment
The clinical evidence is clear that the greatest benefit from GLP-1 therapy comes from long-term, continuous use. Patients who stop therapy regain most of their weight within a year. If side effects are the reason you stopped — or the reason you haven’t started — that is a clinical problem worth solving with a licensed provider rather than waiting years for a new drug class.
Common provider-level interventions that help patients stay on GLP-1 therapy:
- Switching molecules: Some patients tolerate tirzepatide better than semaglutide, or vice versa, despite similar mechanisms. The GI profiles differ enough to be worth trying.
- Dose adjustment: A provider can pause titration, reduce dose temporarily, or prescribe a lower-than-maximum maintenance dose that preserves most efficacy while reducing side effects.
- Foundayo (oral orforglipron): For patients with needle aversion contributing to anxiety around injections, the oral GLP-1 pill approved in April 2026 eliminates injection-site effects, though its oral GI effects are roughly comparable to injections.
- Structured dietitian support: Co-enrollment in a nutrition counseling program reduces nausea rates in clinical practice.
An Omnia TeleHealth provider can review your medication history, current symptoms, and goals, then recommend whether a dose adjustment, molecule switch, or combination approach makes the most sense for you. You can learn more about our telehealth weight loss programs and get started online.
Frequently Asked Questions
Is petrelintide FDA-approved? No. As of October 2026, petrelintide is an investigational drug in Phase 3 clinical trials. It is not commercially available in the United States. The earliest possible FDA approval, assuming successful Phase 3 results and standard review timelines, would be 2028 or later.
How does amylin differ from GLP-1? GLP-1 (glucagon-like peptide-1) primarily acts on receptors in the gut, pancreas, and brain to slow gastric emptying, lower glucagon, and increase satiety. Amylin acts on receptors in a different brain region (area postrema) and uses complementary signaling pathways. The two hormones work through separate circuits, which is why researchers believe combining them may produce additive weight loss.
Why did the petrelintide trial show less weight loss than Ozempic or Zepbound? The ZUPREME-1 trial was 42 weeks; most GLP-1 pivotal trials ran 68–72 weeks, which allows more time for weight to accrue. Additionally, GLP-1 agonists have a more potent appetite-suppressing effect at the approved doses. Petrelintide’s potential advantage is tolerability, not outright efficacy — though combination regimens may change that picture.
Are there other amylin-based drugs in development? Zealand Pharma is developing dasiglucagon (a glucagon analog) and other peptides in the metabolic space, and several other companies are exploring amylin + GLP-1 fixed-dose combinations. The amylin mechanism has renewed pharmaceutical interest after petrelintide’s positive Phase 2 data.
Can I get on a clinical trial for petrelintide? Roche’s Phase 3 ZUPREME trials are actively enrolling. You can search for open sites at ClinicalTrials.gov using the search term “petrelintide.” Eligibility typically requires a BMI of 27 or higher with a weight-related condition, or BMI of 30 or higher.
Petrelintide represents a genuine advance in the obesity treatment pipeline, but it is not a near-term clinical option. If you’re ready to address your weight health today, our board-certified providers can guide you through the full range of currently available, FDA-approved approaches — including semaglutide, tirzepatide, oral orforglipron, and medically supervised lifestyle support. Schedule a consultation with Omnia TeleHealth to get started.